QTc Prolongation and Psychiatric Medications: A Basic Primer for Psychiatrists-View Course References

View Course References

Pdf Summary

This document references numerous studies and articles on the relationship between psychiatric medications and QTc prolongation, which is a risk factor for potentially fatal ventricular arrhythmias. Some key findings from these studies include:<br /><br />- Propoxyphene can induce torsades de pointes (Adler et al., 2011).<br />- Corrected QT interval prolongation can occur during methadone and buprenorphine treatment (Anchersen et al., 2009).<br />- Methadone and buprenorphine may affect electrocardiogram characteristics (Athanasos et al., 2008).<br />- Citalopram's effects on QT interval can be influenced by guidance (Austin et al., 2014).<br />- Buprenorphine and antiretroviral agents can affect QT interval (Baker et al., 2006).<br />- Antipsychotic dose is associated with QT interval prolongation (Barbui, 2016).<br />- Overdoses of oxcarbazepine and atomoxetine with quetiapine can lead to torsades de pointes (Barker et al., 2004).<br />- Trazodone overdose can lead to prolonged QTc interval (Dattilo et al., 2007).<br />- EKG monitoring is important for patients on methadone therapy (Cruciani et al., 2005).<br />- Psychotropic medications can cause QT prolongation and torsades de pointes (Beach et al., 2018).<br />- Second-generation antipsychotics and antidepressants are associated with QT prolongation (Hasnain et al., 2014).<br />- There is a risk of sudden cardiac death associated with antipsychotics and antidepressants (Leonard et al., 2013).<br />- Several antiepileptic drugs can affect QTc interval (Chen et al., 2018).<br />- Corrected QT interval may be influenced by lithium and valproate in psychiatric patients (Chen et al., 2020; Kurt et al., 2009).<br />- Cardiac adverse effects can occur with ADHD medications (Weisler et al., 2005; Scherer et al., 2009).<br /><br />These studies highlight the importance of monitoring and managing QT interval prolongation in patients taking psychiatric medications, especially those at higher risk. The findings also emphasize the need for clinicians to be aware of the potential cardiac effects of these medications when prescribing them to patients.

Keywords

psychiatric medications

QTc prolongation

ventricular arrhythmias

torsades de pointes

methadone

buprenorphine

antipsychotic dose

sudden cardiac death

antiepileptic drugs

ADHD medications